Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging

被引:132
作者
Adams, JY
Johnson, M
Sato, M
Berger, F
Gambhir, SS
Carey, M
Iruela-Arispe, ML
Wu, L [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Crump Inst Mol Imaging, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA
[5] Univ Calif Los Angeles, Coll Letters & Sci, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA
关键词
D O I
10.1038/nm743
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Non-invasive imaging and transcriptional targeting can improve the safety of therapeutic approaches in cancer. Here we demonstrate the ability to identify metastases in a human-prostate cancer model, employing a prostate-specific adenovirus vector (AdPSE-BC-luc) and a charge-coupled device-imaging system. AdPSE-BC-luc, which expresses firefly luciferase from an enhanced prostate-specific antigen promoter, restricted expression in the liver but produced robust signals in prostate tumors. In fact, expression was higher in advanced, androgen-independent tumors than in androgen-dependent lesions. Repetitive imaging over a three-week period after AdPSE-BC-luc injection into tumor-bearing mice revealed that the virus could locate and illuminate metastases in the lung and spine. Systemic injection of low doses of AdPSE-BC-luc illuminated lung metastasis. These results demonstrate the potential use of a non-invasive imaging modality in therapeutic and diagnostic strategies to manage prostate cancer.
引用
收藏
页码:891 / 896
页数:6
相关论文
共 20 条
  • [1] Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: Based on a Canadian randomized trial with palliative end points
    Bloomfield, DJ
    Krahn, MD
    Neogi, T
    Panzarella, T
    Smith, TJ
    Warde, P
    Willan, AR
    Ernst, S
    Moore, MJ
    Neville, A
    Tannock, IF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) : 2272 - 2279
  • [2] Craft N, 1999, CANCER RES, V59, P5030
  • [3] A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
    Craft, N
    Shostak, Y
    Carey, M
    Sawyers, CL
    [J]. NATURE MEDICINE, 1999, 5 (03) : 280 - 285
  • [4] FREIDMANN T, 1999, DEV HUMAN GENE THERA
  • [5] Gregory CW, 2001, CANCER RES, V61, P4315
  • [6] Gene therapy for prostate cancer: Current status and future prospects
    Harrington, KJ
    Spitzweg, C
    Bateman, AR
    Morris, JC
    Vile, RG
    [J]. JOURNAL OF UROLOGY, 2001, 166 (04) : 1220 - 1233
  • [7] Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice
    Klein, KA
    Reiter, RE
    Redula, J
    Morad, H
    Zhu, XL
    Brothman, AR
    Lamb, DJ
    Marcelli, M
    Belldegrun, A
    Witte, ON
    Sawyers, CL
    [J]. NATURE MEDICINE, 1997, 3 (04) : 402 - 408
  • [8] Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma
    Leav, I
    Lau, KM
    Adams, JY
    McNeal, JE
    Taplin, ME
    Wang, JF
    Singh, H
    Ho, SM
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (01) : 79 - 92
  • [9] Linja MJ, 2001, CANCER RES, V61, P3550
  • [10] The role of prostate specific antigen measurement in the detection and management of prostate cancer
    Nash, AF
    Melezinek, I
    [J]. ENDOCRINE-RELATED CANCER, 2000, 7 (01) : 37 - 51